— Know what they know.
Not Investment Advice

MIST NASDAQ

Milestone Pharmaceuticals Inc.
1W: +2.7% 1M: -31.4% 3M: -38.7% YTD: -55.5% 1Y: -52.1% 3Y: -72.7% 5Y: -84.9%
$0.81
-0.01 (-0.74%)
 
Weekly Expected Move ±8.3%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 32 · $100.8M mcap · 123M float · 1.15% daily turnover · Short 55% of daily vol
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$100.8M
52W Range0.752-3.06
Volume768,238
Avg Volume1,415,833
Beta0.98
Dividend—
Analyst Ratings
6 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOJoseph G. Oliveto
Employees38
SectorHealthcare
IndustryBiotechnology
IPO Date2019-05-09
1111 Dr. Frederik-Philips Boulevard
Montreal, QC H4M 2X6
CA
15143360444
About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.

Recent Insider Trades

NameTypeSharesPriceDate
Giles Lisa M. A-Award 77,000 $1.22 2026-06-10
Fischer Seth H. Z. A-Award 77,000 $1.22 2026-06-10
Duty Stuart A-Award 77,000 $1.22 2026-06-10
Wills Robert James A-Award 77,000 $1.22 2026-06-10
TOMSICEK MICHAEL JOH A-Award 77,000 $1.22 2026-06-10

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms